BARCELONA, Spain Lotte Biologics will begin antibody-drug conjugate manufacturing at its site near Syracuse, New York, starting in the first quarter of 2025, according to CEO Lee Won-jik, who also goes by Richard Lee. The company expects its ADC production to account for some 10 percent of its total sales in 10 years, Lee added. “Lotte Biologics is building an ADC facility within its Syracuse facilities. The.
Daewoong Pharmaceutical announced that the company aims for annual sales of its two new drugs, gastroesophageal reflux treatment Fexuclue and diabetes drug Envlo, to reach 1 trillion won ($736 million) by 2030. "Daewoong Pharmaceutical anticipates new launches and outlicensing deals involving Fexuclue and Envlo in the global pharmaceutical market," said Kim Do-young, head of Daewoong Pharmaceutical's G.